With single-cell transcriptomic, T cell receptor, and B cell receptor data, researchers tracked immune shifts in tissue and peripheral blood samples from ulcerative colitis patients.
Based in Boston with operations in Ireland and Iceland, the reorganized company is supporting COVID-19 testing and population genomics as it sheds its China division.
The multi-omics translational software developer is helping the Crohn's & Colitis Foundation validate its research into biomarkers that can predict complications requiring surgery.
The test is designed to analyze the expression of 17 genes in order to differentiate mild and aggressive forms of Crohn's disease and ulcerative colitis.
The company has raised $30 million to date to fund development and commercialization of its molecular diagnostic test to predict response to anti-TNF therapies.
The study will recruit up to 200 patients with active Crohn's disease or ulcerative colitis and sort them into high- and low-risk cohorts using the PredictSure IBD test.
Under the deal, KSL will commercialize and facilitate orders of the PredictSURE IBD test throughout North America and will also process all samples through its laboratory, KSL Diagnostics.
Under the expanded deal, PredictImmune will have first right of refusal on technologies for predicting disease outcome for systemic lupus erythematosus.
